SCHEMBL541416

SCHEMBL541416

O=C(c1cnc(N[C@H]2C[C@@H]3CC[C@H]2O3)nc1C(F)(F)F)N1CC(F)(F)C(F)(F)C1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 1/20 0.37
▸ VNN1 O95497 3/20 0.35
▸ SCD O00767 1/20 0.34
▸ PDE5A O76074 1/20 0.34
▸ PDE9A O76083 1/20 0.34
▸ CNR2 P34972 10/20 0.33
▸ CYP1A2 P05177 3/20 0.33
▸ CYP2D6 P10635 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ CYP2C9 P11712 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ HCRTR1 O43613 1/20 0.32
▸ HCRTR2 O43614 1/20 0.32
▸ TNF P01375 2/20 0.32
▸ IRAK4 Q9NWZ3 2/20 0.32
▸ JUN P05412 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32
▸ RELA Q04206 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12796394 1.00 CXCR4 (0.37) CXCR4VNN1SCDPDE5APDE9A
SCHEMBL12796397 0.89 VNN1 (0.37) CXCR4VNN1SCDPDE5APDE9A
SCHEMBL12796398 0.89 SCD (0.39) CXCR4VNN1SCDPDE5APDE9A
SCHEMBL12796373 0.87 LRRK2 (0.41) CXCR4SCDCNR2CYP1A2CYP2D6
SCHEMBL12796381 0.87 LRRK2 (0.41) CXCR4SCDCNR2CYP1A2CYP2D6
SCHEMBL12796374 0.85 CXCR4 (0.37) CXCR4SCDPDE5APDE9ACNR2
SCHEMBL12796366 0.85 CXCR4 (0.37) CXCR4SCDPDE5APDE9ACNR2
SCHEMBL12796026 0.84 PDE5A (0.44) PDE5APDE9ACNR2CYP1A2CYP2D6
SCHEMBL12796021 0.84 PDE5A (0.44) PDE5APDE9ACNR2CYP1A2CYP2D6
SCHEMBL12795985 0.81 MAPT (0.47) PDE5APDE9ACNR2CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310373-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-21 — — US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 — — US disclosed
EP-2415765-A1 PYRIMIDINE COMPOUND Astellas Pharma Inc. (JP) 2012-02-08 — — EP disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053912-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 CXCR4 350/4885VNN1 3256/4885SCD 1093/4885
US-20130310373-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 CXCR4 206/4885VNN1 2974/4885SCD 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback